FRASSOLDATI, ALESSIO
 Distribuzione geografica
Continente #
AS - Asia 115
NA - Nord America 111
EU - Europa 70
AF - Africa 10
SA - Sud America 9
Totale 315
Nazione #
US - Stati Uniti d'America 109
SG - Singapore 65
CN - Cina 18
IT - Italia 18
HK - Hong Kong 10
SE - Svezia 10
DE - Germania 9
VN - Vietnam 9
GB - Regno Unito 8
BR - Brasile 5
CI - Costa d'Avorio 5
FI - Finlandia 5
IN - India 5
NL - Olanda 5
IE - Irlanda 4
TG - Togo 4
CH - Svizzera 3
FR - Francia 3
RU - Federazione Russa 3
CA - Canada 2
EC - Ecuador 2
JO - Giordania 2
AR - Argentina 1
BG - Bulgaria 1
BO - Bolivia 1
GE - Georgia 1
ID - Indonesia 1
JP - Giappone 1
KZ - Kazakistan 1
LT - Lituania 1
NG - Nigeria 1
TR - Turchia 1
UZ - Uzbekistan 1
Totale 315
Città #
Singapore 54
Ashburn 19
Chandler 17
Hong Kong 10
Beijing 7
Santa Clara 7
Bagnacavallo 6
Abidjan 5
Bologna 4
Dublin 4
Fairfield 4
Helsinki 4
Lomé 4
Redondo Beach 4
Southend 4
Bentivoglio 3
Boardman 3
Princeton 3
Amman 2
Bern 2
Chicago 2
Hanoi 2
Ho Chi Minh City 2
Nuremberg 2
Turin 2
Abeokuta 1
Ankara 1
Berlin 1
Bexley 1
Biên Hòa 1
Bragado 1
Bremen 1
Bühl 1
Cajamar 1
Cambridge 1
Canoas 1
Castel Maggiore 1
Cochabamba 1
Dallas 1
Denver 1
Des Moines 1
Florence 1
Frankfurt am Main 1
Guayaquil 1
Itabela 1
Jinan 1
Kansas City 1
Karaganda 1
La Joya de Los Sachas 1
Lappeenranta 1
Lauterbourg 1
Leawood 1
Leicester 1
Los Angeles 1
Milan 1
Nam Định 1
Nanyang 1
New York 1
North Bergen 1
Olalla 1
Orem 1
Osasco 1
Ottawa 1
Paulista 1
Poplar 1
Portsmouth 1
Raleigh 1
Redmond 1
Saint Louis 1
San Diego 1
San Jose 1
Seattle 1
Shanwei 1
Shijiazhuang 1
Sofia 1
Tashkent 1
Tbilisi 1
Thành Phố Bà Rịa 1
Tiền Giang 1
Tokyo 1
Toronto 1
Washington 1
Wilmington 1
Xi'an 1
Totale 235
Nome #
Phase II study of eribulin in combination with gemcitabine for the treatment of patients with locally advanced or metastatic triple negative breast cancer (ERIGE trial). Clinical and pharmacogenetic results on behalf of the Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC) 129
null 98
Correction to: Phase 2 study of NAB-paclitaxel in SensiTivE and refractory relapsed small cell lung cancer (SCLC) (NABSTER TRIAL) (British Journal of Cancer, (2020), 123, 1, (26-32), 10.1038/s41416-020-0845-3) 46
Erratum to: Survival prediction in high-grade gliomas using CT perfusion imaging [J Neurooncol (2015) 123, 93-102, DOI 10.1007/s11060-015-1766-5] 42
Early prediction of endocrine responsiveness in ER+/HER2-negative metastatic breast cancer (MBC): pilot study with 18F-fluoroestradiol (18F-FES) CT/PET 8
Totale 323
Categoria #
all - tutte 1.162
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 1.162


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20215 0 0 0 0 0 0 0 0 4 0 0 1
2021/202243 0 0 1 4 3 1 0 11 2 4 11 6
2022/202351 3 7 1 8 4 5 1 2 10 2 5 3
2023/202431 1 4 1 13 2 6 1 1 0 0 2 0
2024/202586 5 11 8 3 12 5 6 5 2 11 3 15
2025/2026107 17 7 11 26 40 6 0 0 0 0 0 0
Totale 323